Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 [Update on chemotherapy for bladder cancer. Update 2010].

Literature DB >> 20859610

[Update on chemotherapy for bladder cancer. Update 2010].

Abstract

This review summarizes results of neoadjuvant and adjuvant trials for locally advanced bladder cancer as well as data on systemic chemotherapy for metastatic urothelial cancer. Increasing attention has been drawn to targeted cancer therapies in the treatment of urothelial cancer in recent years. In future, molecular profiling will play a major role as a means to tailor individual therapy.

Entities: Disease

Mesh：

Year: 2010 PMID： 20859610 DOI： 10.1007/s00120-010-2380-y

Source DB: PubMed Journal: Urologe A ISSN： 0340-2592 Impact factor: 0.639

18 in total

1. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Authors:
Journal: Eur Urol Date: 2005-04-25 Impact factor: 20.096

2. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.

Authors: Takahito Suyama; Takeshi Ueda; Satoshi Fukasawa; Yusuke Imamura; Kazuyoshi Nakamura; Kyoko Miyasaka; Tomokazu Sazuka; Ken-ichi Egoshi; Naoki Nihei; Masaaki Hamano; Tomohiko Ichikawa; Masayuki Maruoka
Journal: Jpn J Clin Oncol Date: 2009-02-10 Impact factor: 3.019

3. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.

Authors: Robert Dreicer; Hailun Li; Mark Stein; Robert DiPaola; Michael Eleff; Bruce J Roth; George Wilding
Journal: Cancer Date: 2009-09-15 Impact factor: 6.860

4. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

Authors: Christian Wülfing; Jean-Pascal H Machiels; Dirk J Richel; Marc-Oliver Grimm; Uwe Treiber; Marco R De Groot; Philippe Beuzeboc; Roma Parikh; Frank Pétavy; Iman A El-Hariry
Journal: Cancer Date: 2009-07-01 Impact factor: 6.860

Review 5. Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors.

Authors: Joaquim Bellmunt; Francois-Michel Delgado; Claude George
Journal: Semin Oncol Date: 2008-06 Impact factor: 4.929

6. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.

Authors: Matthew I Milowsky; David M Nanus; Fernando C Maluf; Svetlana Mironov; Weiji Shi; Alexia Iasonos; Jamie Riches; Ashley Regazzi; Dean F Bajorin
Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544

7. A phase II trial of continuous 5-fluorouracil in recurrent or metastatic transitional cell carcinoma of the urinary tract.

Authors: M S Highley; G O Griffiths; B M Uscinska; R A Huddart; J B P Barber; M K B Parmar; P G Harper
Journal: Clin Oncol (R Coll Radiol) Date: 2009-03-09 Impact factor: 4.126

8. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis.

Authors: Fabrice Andre; Kristine Broglio; Henri Roche; Miguel Martin; John R Mackey; Frederique Penault-Llorca; Gabriel N Hortobagyi; Lajos Pusztai
Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544

9. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.

Authors: David C Smith; Niklas J Mackler; Rodney L Dunn; Maha Hussain; David Wood; Cheryl T Lee; Martin Sanda; Ulka Vaishampayan; Daniel P Petrylak; David I Quinn; Kathleen Beekman; James E Montie
Journal: J Urol Date: 2008-10-18 Impact factor: 7.450

10. Vinflunine in the treatment of bladder cancer.

Authors: Mark Bachner; Maria De Santis
Journal: Ther Clin Risk Manag Date: 2008-12 Impact factor: 2.423

2 in total

1. [Bladder cancer update: what was new at the 2010 annual congress of the German Association of Urology in Düsseldorf?].

Authors: R Nawroth; A Hartmann; P J Olbert; A S Merseburger; R Stöhr; R Knüchel; M Retz; S Füssel
Journal: Urologe A Date: 2011-02 Impact factor: 0.639

2. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?

Authors: Michael Rink; Shahrokh F Shariat; Evanguelos Xylinas; John P Fitzgerald; Jens Hansen; David A Green; Ashish M Kamat; Giacomo Novara; Siamak Daneshmand; Yves Fradet; Scott T Tagawa; Patrick J Bastian; Wassim Kassouf; Quoc-Dien Trinh; Pierre I Karakiewicz; Hans-Martin Fritsche; Derya Tilki; Felix K Chun; Bjoern G Volkmer; Marko Babjuk; Axel S Merseburger; Douglas S Scherr; Yair Lotan; Robert S Svatek
Journal: World J Urol Date: 2012-07-26 Impact factor: 4.226

2 in total